Peptide therapy claims on TikTok: what pharmacists get right and wrong

What did @megamindpharmacist actually say?

The pharmacist's core argument is simple: peptides might be promising, but there's no safety infrastructure in Australia to support people who run into trouble using them. Using a car analogy, they warned that if something goes wrong, emergency departments won't know what to do. Their bottom line: "I personally do not recommend you use it" until these compounds are approved, prescribed, and manufactured in a regulated pharmaceutical facility.

They specifically named BPC-157, TB-500, GHK-Cu, and a compound they called "Rhetatrui Tides" (likely retatrutide, a GIP/GLP-1/glucagon triple agonist in clinical trials). They also made a pointed pharmacology claim: "all medicines are poisons in low doses" and insisted that anyone denying peptides are medicines needs more education.

Does the science back this up?

On the core regulatory and safety concern, the evidence strongly supports their position. On the pharmacology claim, they got the quote backwards, but the spirit is correct.

First, the regulatory reality in Australia: the Therapeutic Goods Administration (TGA) has not approved BPC-157, TB-500, or GHK-Cu for human use. They are not on the Australian Register of Therapeutic Goods. Research-grade peptides sold online are frequently mislabeled or contaminated. A 2018 study by Cohen et al. in JAMA Internal Medicine analyzed 44 sports supplement products and found significant discrepancies between labeled and actual contents, a problem that extends to the peptide market.

Second, the pharmacology slip. The creator said "all medicines are poisons in low doses." They almost certainly meant Paracelsus's foundational toxicology principle: the dose makes the poison, meaning substances become harmful at high doses, not low ones. The inversion doesn't change their broader point, but it is technically wrong as stated.

Third, on retatrutide specifically: it is currently in Phase 2 and Phase 3 trials (Jastreboff et al., 2023, New England Journal of Medicine). It is not approved anywhere for clinical use yet. Recommending caution here is entirely appropriate.

What did they get wrong (or right)?

They got the big picture right. The regulatory gap they describe is real, the quality-control problem is documented, and the emergency care concern is legitimate and underappreciated.

What they got wrong is minor but worth noting. The Paracelsus quote was inverted. "All medicines are poisons in low doses" is the opposite of the actual principle. This is a common misquote, not a dangerous one, but it matters if a pharmacist is correcting others on pharmacology education.

They also made a sweeping claim that emergency physicians "don't even know what" peptides like retatrutide are. That may be true in many settings, but some academic emergency departments do have toxicology resources and can contact poison control centers for novel compounds. The concern is valid; the absolute framing slightly overstates it.

Credit where it is due: the "esky in the boot of their car" line is not just colorful. Cold-chain integrity is a real issue for peptides. BPC-157 and TB-500 are typically stored lyophilized and reconstituted, and improper temperature exposure degrades them. The creator is pointing at a genuine pharmaceutical manufacturing concern, not just being dramatic.

What should you actually know?

If you are considering peptide therapy, here is what the evidence and regulatory picture actually look like right now.

BPC-157 has shown tissue-healing effects in rodent models (Sikiric et al., 2018, Current Pharmaceutical Design), but there are no completed randomized controlled trials in humans. TB-500, a thymosin beta-4 fragment, has similar animal data with no human trial evidence. GHK-Cu has in vitro data supporting wound healing and collagen synthesis, but again, human clinical evidence is limited. Retatrutide is the most clinically developed compound named in the video, with actual human trial data showing significant weight loss, but it is not yet approved anywhere.

The quality problem is not hypothetical. A 2021 analysis of peptide products sold online found that a meaningful proportion contained incorrect concentrations or bacterial endotoxins (Cannataro et al., 2021, Nutrients). Injecting a contaminated peptide carries real infection and immune reaction risks that no amount of "trust me, bro" sourcing resolves.

The pharmacist's advice to wait for proper approval before using these compounds is conservative but defensible. Telehealth platforms operating in regulated frameworks can offer peptide therapies where they are legally permitted, with physician oversight, pharmaceutical-grade sourcing, and monitoring. That is a meaningfully different risk profile than buying lyophilized powder from an online vendor.